Date: 2013-07-09
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: emibetuzumab (LY2875358)
Action
mechanism: monoclonal antibody. Emibetuzumab (LY2875358) is a monoclonal MET antibody with no functional agonistic activity designed to block both ligand-dependent and ligand-independent MET signaling by its dual mode of action
Disease: non-small cell lung cancer (NSCLC)
Therapeutic area: Cancer - Oncology
Country: Denmark, France, Germany, Italy, Korea, Republic of, Netherlands, Spain, Taiwan, UK
Trial
details: The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone. Participants will have Non-Small Cell Lung Cancer (NSCLC) that has advanced to Stage IV. Participants should not have been treated with drugs for Stage IV NSCLC, previously. All participants will get erlotinib alone, for approximately 8 weeks. Participants with radiographic disease control at the end of the erlotinib lead-in study period will be randomly assigned to receive LY2875358 plus erlotinib or erlotinib alone. Participants, who were chosen to receive erlotinib, alone, may cross over to the combination treatment at the time of progression. (NCT01897480)
Latest
news: * On July 9, 2013, a Phase 2 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov foremibetuzumab (LY2875358) and is currently recruiting participants.
